Kalaris Therapeutics Inc (KLRS)
Kalaris Therapeutics Inc operates in the Biotechnology industry of the Healthcare sector, headquartered in Berkeley Heights, NJ, US. The stock last traded at $3.97, up 0.76% on the session, giving a market capitalisation of $86.7M. On trailing twelve-month figures it carries a trailing P/E of -1.85, a net margin of 0.0%. Its beta of 0.19 implies it has historically moved less than the broad market.
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), as well as for the treatment of other exudative and neovascular retinal diseases.
Kalaris Therapeutics Inc is most often compared with the following Healthcare names: